Aldeyra Shifts Focus to Commercialization, With Upcoming FDA Decision on Reproxalap a Potential Catalyst

Aldeyra's 52% reduction in R&D spending signals a shift from drug development to commercialization readiness, with the upcoming PDUFA decision for reproxalap as a potential catalyst.

With $151.7M cash on hand and an estimated 40-month runway, Aldeyra has financial stability despite market cap shrinkage to $382.63M.

Approaching FDA milestones like the November PDUFA date for reproxalap in dry eye disease represent pivotal catalysts for Aldeyra.

Reproxalap's first-in-class RASP inhibition mechanism gives it a unique edge in multi-billion dollar dry eye and allergic conjunctivitis markets.

Despite risks like regulatory uncertainty and competition, Aldeyra remains a "Buy" for long-term investors, with significant upside if reproxalap gains approval.